Alzheimer's disease

News

Roche ducks out of AC Immune Alzheimer's antibody alliance

After almost 18 years of collaboration, Roche’s Genentech unit has ended a collaboration with AC Immune on Alzheimer’s disease therapies, handing back rights to two antibo

News

CHMP calls in advisors to assist in Leqembi review

Eisai and Biogen’s marketing application for Alzheimer’s disease therapy Leqembi will face an independent advisory committee convened by the EMA before a decision is made

News

China is third country to approve Alzheimer’s drug Leqembi

Eisai and Biogen have a third regulatory approval for their amyloid-targeting Alzheimer’s disease therapy Leqembi, after it was greenlit by China’s National Medical Produc

News

Eisai working on wristband sensor for brain amyloid

Eisai has joined forces with Oita University in Japan to develop a machine-learning tool that may be able to predict whether someone is at risk of developing Alzheimer’s d

News

Eisai sets Leqembi price in Japan at a discount to US

Eisai and Biogen’s Alzheimer’s disease therapy Leqembi is due to be launched in Japan, its second market, on 20th December, and will be priced quite a lot lower there than

News

Undiagnosed dementia in UK needs drastic action, says review

A just-published report has found that more than a third (36%) of people currently living with dementia in the UK are undiagnosed, and major changes are needed to overturn

Roche ducks out of AC Immune Alzheimer's antibody alliance

CHMP calls in advisors to assist in Leqembi review

China is third country to approve Alzheimer’s drug Leqembi

Eisai working on wristband sensor for brain amyloid

Eisai sets Leqembi price in Japan at a discount to US

Undiagnosed dementia in UK needs drastic action, says review

Lilly bags FDA okay for Wegovy pill rival orforglipron

Using AI-driven synthetic personas to take your insights fur...

Alzheimer's disease

Editor's Picks